SCN8A encephalopathy OMIM 614558
In SCN8A encephalopathy OMIM 614558 (SCN8A, OMIM 614558), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5555, γ 1.4907, spinodal 0.7005). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for SCN8A encephalopathy OMIM 614558 is an R19 double-well emerged from the real proximal-promoter DNA of SCN8A. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
- emergent axis
- ↑ UP [F]
- healthy branch
- OFF
- lesion
- GOF
- γ (stiffness)
- 1.4907
- barrier
- 0.5555
- spinodal
- 0.7005
- s_on / s_off
- 1.2209 / -1.2209
- fragility
- 0.20
- corrective polarity
- clear
- forced direction
- lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5555 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Agents mapped onto the lever
| agent (class) | dir. | status | phase | map |
|---|---|---|---|---|
| voltage-gated sodium-channel inhibition reducing the excess Nav1.6 sodium current of the SCN8A gain Larsen 2015 Neurology 84:480 (the phenotypic spectrum of scn8a encephalopathy); Veeramah 2012 Am J Hum Genet 90:502 (de novo pathogenic scn8a mutation identified by) | decrease | established standard of care | 0 | ✓ in use |
Evidence & provenance
| element | grade | basis |
|---|---|---|
| R19 switch & cusp geometry (this page) | [V] verified | emerged from measured promoter γ of SCN8A; deterministic, 2×sha256 identical |
| corrective direction | [F] forced | forced by the cusp sign; falsifiable (see lever falsifiers) |
| mapped agents / leads | [O] open | direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude |
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).